{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:22:05Z","timestamp":1758403325389,"version":"3.41.2"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.579894","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T05:49:56Z","timestamp":1601012996000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab"],"prefix":"10.3389","volume":"11","author":[{"given":"Maria Grazia","family":"Narducci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Frezzolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Scala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Passarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Bonmassar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Monopoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pina","family":"Accetturi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Cantonetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Carlo","family":"Antonini Cappellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"De Galitiis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rosato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Picozza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giandomenico","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"D\u2019Atri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ejso.2016.07.145","article-title":"Immunotherapy in melanoma: recent advances and future directions.","volume":"43","author":"Franklin","year":"2017","journal-title":"Eur J Surg Oncol."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome.","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/imm.12788","article-title":"PD-1\/PD-L1 inhibitors in haematological malignancies: update 2017.","volume":"152","author":"Jelinek","year":"2017","journal-title":"Immunology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase ib study.","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00277-017-2929-6","article-title":"Successful treatment of refractory Sezary syndrome by anti-PD-1 antibody (nivolumab).","volume":"96","author":"Shen","year":"2017","journal-title":"Ann Hematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1080\/10428194.2018.1516879","article-title":"Response to pembrolizumab and lenalidomide in advanced refractory mycosis fungoides.","volume":"60","author":"Fountain","year":"2019","journal-title":"Leukem Lymph."},{"key":"B7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: a multicenter phase II study.","volume":"20","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nature24649","article-title":"PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis.","volume":"552","author":"Wartewig","year":"2017","journal-title":"Nature."},{"key":"B9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jdcr.2018.01.016","article-title":"Cutaneous CD56+ T-cell lymphoma developing during pembrolizumab treatment for metastatic melanoma.","volume":"4","author":"Zheng","year":"2018","journal-title":"JAAD Case Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00277-018-3406-6","article-title":"\u03b3\u03b4 T cell clonal proliferation early after PD-1 blockade.","volume":"98","author":"Ono","year":"2019","journal-title":"Ann Hematol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000104","article-title":"T-cell lymphoma secondary to checkpoint inhibitor therapy.","volume":"8","author":"Anand","year":"2020","journal-title":"J Immuno Therapy Cancer."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and s\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model.","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936.","volume":"17","author":"van Dongen","year":"2003","journal-title":"Leukemia."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749.An","article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas.","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood."},{"key":"B16","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria.","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.59125","article-title":"Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.","volume":"3","author":"Osa","year":"2018","journal-title":"JCI Insight."},{"key":"B20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:33.0.CO;2-9","article-title":"The Ki-67 Protein: from the known and the unknown.","volume":"182","author":"Scholzen","year":"2000","journal-title":"J Cell Physiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.celrep.2015.05.022","article-title":"Mapping the diversity of follicular helper T cells in human blood and tonsils using high-dimensional mass cytometry analysis.","volume":"11","author":"Wong","year":"2015","journal-title":"Cell Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion.","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jdcr.2019.11.005","article-title":"Pembrolizumab-associated tumor development in a patient with S\u00e9zary syndrome.","volume":"6","author":"Malachowski","year":"2020","journal-title":"JAAD Case Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1182\/blood.2019002038","article-title":"Rapid progression of adult T-cell leukemia\/lymphoma as tumor-infiltrating Tregs after PD-1 blockade.","volume":"134","author":"Rauch","year":"2019","journal-title":"Blood."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult T-cell leukemia\u2013lymphoma after PD-1 inhibitor therapy.","volume":"378","author":"Ratner","year":"2018","journal-title":"New England J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti- PD-1 response.","volume":"545","author":"Huang","year":"2017","journal-title":"Nature."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1738797","article-title":"Blockade of programmed cell death protein 1 (PD-1) in S\u00e9zary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation.","volume":"9","author":"Saulite","year":"2020","journal-title":"OncoImmunology."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41375-018-0305-8","article-title":"Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K\/AKT\/mTORC1 pathway and its prognostic relevance.","volume":"33","author":"Cristofoletti","year":"2018","journal-title":"Leukemia."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-016-0201-6","article-title":"Challenges and opportunitiesfor checkpoint blockade in T-cell lymphoproliferative disorders.","volume":"4","author":"Phillips","year":"2016","journal-title":"J Immuno Therapy Cancer."},{"key":"B30","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","article-title":"CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review.","volume":"234","author":"Farhood","year":"2019","journal-title":"J Cell Physiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","article-title":"In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1172\/JCI129338","article-title":"Killers 2.0: NK cell therapies at the forefront of cancer control.","volume":"129","author":"Hodgins","year":"2019","journal-title":"J Clin Investigat."},{"key":"B33","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/jid.2008.256","article-title":"NKG2D ligands expression and NKG2D-mediated NK activity in Sezary patients.","volume":"129","author":"Dulphy","year":"2009","journal-title":"J Investigat Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint.","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20225731","article-title":"Melanoma and vitiligo: in good company.","volume":"20","author":"Failla","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jdcr.2015.02.009","article-title":"Complete regression of mycosis fungoides after ipilimumab therapy for advanced melanoma.","volume":"1","author":"Bar-Sela","year":"2015","journal-title":"JAAD Case Rep."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040804","article-title":"Hyperprogression under immune checkpoint-based immunotherapy\u2014current understanding, the role of pd-1\/pd-l1 tumour-intrinsic signalling, future directions and a potential large animal model.","volume":"12","author":"Kocikowski","year":"2020","journal-title":"Cancers."},{"key":"B38","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell\u2013mediated immunotherapy.","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discovery."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1182\/blood-2013-06-510578","article-title":"Comprehensive analysis of PTEN status in Sezary syndrome.","volume":"122","author":"Cristofoletti","year":"2013","journal-title":"Blood."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1038\/onc.2015.462","article-title":"Oncogenic PTEN functions and models in T-cell malignancies.","volume":"35","author":"Tesio","year":"2016","journal-title":"Oncogene."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma.","volume":"9","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of S\u00e9zary syndrome identifies alterations of key T cell signaling and differentiation genes.","volume":"12","author":"Wang","year":"2015","journal-title":"Nat Genet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.579894\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T05:49:58Z","timestamp":1601012998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.579894\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2020.579894"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.579894","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2020,9,25]]},"article-number":"579894"}}